UroGen Pharma Ltd. (NASDAQ:URGN) Short Interest Down 29.9% in May

UroGen Pharma Ltd. (NASDAQ:URGN - Get Free Report) was the target of a significant decline in short interest during the month of May. As of May 31st, there was short interest totalling 3,920,000 shares, a decline of 29.9% from the May 15th total of 5,590,000 shares. Based on an average daily trading volume, of 1,670,000 shares, the days-to-cover ratio is presently 2.3 days. Currently, 17.6% of the shares of the stock are sold short.

Wall Street Analysts Forecast Growth

URGN has been the subject of a number of research reports. D. Boral Capital reiterated a "buy" rating and issued a $25.00 price objective on shares of UroGen Pharma in a research report on Thursday, June 12th. LADENBURG THALM/SH SH initiated coverage on UroGen Pharma in a research report on Wednesday, February 19th. They issued a "buy" rating and a $31.00 price objective for the company. Oppenheimer set a $31.00 price objective on UroGen Pharma and gave the stock a "buy" rating in a research report on Friday. Scotiabank reiterated an "outperform" rating on shares of UroGen Pharma in a research report on Friday. Finally, The Goldman Sachs Group set a $16.00 target price on UroGen Pharma and gave the stock a "neutral" rating in a research report on Friday. One analyst has rated the stock with a hold rating, six have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has an average rating of "Buy" and a consensus price target of $32.86.

UroGen Pharma Price Performance

UroGen Pharma stock opened at $14.34 on Tuesday. UroGen Pharma has a 1 year low of $3.42 and a 1 year high of $19.01. The company has a current ratio of 9.00, a quick ratio of 8.77 and a debt-to-equity ratio of 4.77. The firm has a market capitalization of $661.17 million, a P/E ratio of -4.55 and a beta of 0.40. The business has a 50-day moving average of $8.63 and a 200-day moving average of $10.05.

UroGen Pharma (NASDAQ:URGN - Get Free Report) last released its quarterly earnings data on Monday, May 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.83) by ($0.09). The firm had revenue of $20.25 million during the quarter, compared to analyst estimates of $22.71 million. On average, equities analysts anticipate that UroGen Pharma will post -3.12 EPS for the current year.

Insider Activity at UroGen Pharma

In related news, insider Mark Schoenberg sold 5,162 shares of UroGen Pharma stock in a transaction dated Monday, June 9th. The stock was sold at an average price of $7.37, for a total value of $38,043.94. Following the completion of the sale, the insider now directly owns 153,378 shares in the company, valued at $1,130,395.86. This trade represents a 3.26% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 5.10% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On UroGen Pharma

Several institutional investors have recently modified their holdings of the business. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. lifted its holdings in shares of UroGen Pharma by 4.7% during the 4th quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,667 shares of the company's stock valued at $231,000 after purchasing an additional 969 shares in the last quarter. Wellington Management Group LLP lifted its holdings in shares of UroGen Pharma by 0.8% during the 1st quarter. Wellington Management Group LLP now owns 148,078 shares of the company's stock valued at $1,638,000 after purchasing an additional 1,125 shares in the last quarter. Rhumbline Advisers lifted its holdings in shares of UroGen Pharma by 2.8% during the 4th quarter. Rhumbline Advisers now owns 51,270 shares of the company's stock valued at $546,000 after purchasing an additional 1,402 shares in the last quarter. MetLife Investment Management LLC lifted its holdings in shares of UroGen Pharma by 13.6% during the 4th quarter. MetLife Investment Management LLC now owns 22,766 shares of the company's stock valued at $242,000 after purchasing an additional 2,727 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. lifted its holdings in shares of UroGen Pharma by 3.3% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 93,517 shares of the company's stock valued at $996,000 after purchasing an additional 3,024 shares in the last quarter. Institutional investors own 91.29% of the company's stock.

UroGen Pharma Company Profile

UroGen Pharma Ltd., a biotechnology company, engages in the development and commercialization of solutions for urothelial and specialty cancers. It offers RTGel, a novel proprietary polymeric biocompatible, reverse thermal gelation hydrogel technology to improve therapeutic profiles of existing drugs; and Jelmyto for pyelocalyceal solution.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.